MulticEnter Trial of Rivaroxaban for Early disCharge of pUlmonaRY Embolism From the Emergency Department

Trial Profile

MulticEnter Trial of Rivaroxaban for Early disCharge of pUlmonaRY Embolism From the Emergency Department

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 May 2017

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Pulmonary embolism
  • Focus Therapeutic Use
  • Acronyms MERCURY PE
  • Sponsors Janssen
  • Most Recent Events

    • 28 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 22 Mar 2017.
    • 28 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 20 Jan 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top